Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
WANBURY

Wanbury Share Price

 
Stock Hit Upper Circuit

 

Wanbury live price: ₹269.67. It opened at ₹260 vs previous close ₹258; intraday high/low: ₹271/₹254. The 50 & 200 DMA stand at ₹245.27/₹244.16.

Wanbury Performance

  • Today's Low
  • ₹254
  • Today's High
  • ₹271
  • 52 Week Low
  • ₹162
  • 52 Week High
  • ₹330
  • Open Price₹260
  • Previous Close₹258
  • Volume82,504
  • 50 DMA₹245.27
  • 100 DMA₹243.65
  • 200 DMA₹244.16

Wanbury Chart

Investment Returns

  • Over 1 Month + 8.61%
  • Over 3 Month + 49.62%
  • Over 6 Month + 14.68%
  • Over 1 Year -0.28%

Smart Investing Starts Here Start SIP with Wanbury for Steady Growth!

Invest Now

Wanbury Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.6
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 942
  • P/B Ratio
  • 7.7
  • Average True Range
  • 13.76
  • EPS
  • 12.3
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.86
  • RSI
  • 63.14
  • MFI
  • 71.33

Wanbury Financials

Wanbury Technicals

EMA & SMA

Current Price
₹269.67
+ 11.36 (4.4%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹249.98
  • 50 Day
  • ₹245.27
  • 100 Day
  • ₹243.65
  • 200 Day
  • ₹244.16

Resistance and Support

265.06 Pivot Speed
  • R3 292.75
  • R2 281.98
  • R1 275.83
  • S1 258.91
  • S2 248.14
  • S3 241.99

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wanbury manufactures and markets pharmaceutical products, focusing on active pharmaceutical ingredients (APIs) and formulations. The company serves global markets with a range of therapeutic solutions in areas like anti-diabetics, pain management, and gastrointestinal treatments.

Wanbury has an operating revenue of Rs. 657.69 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 5% is okay, ROE of 51% is exceptional. The company has a high debt to equity of 270%, which can be a reason to worry. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 5% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wanbury Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-05 Quarterly Results
2025-11-13 Quarterly Results
2025-08-04 Quarterly Results
2025-05-15 Audited Results
2025-02-12 Quarterly Results & Others Inter-alia, to consider 1. The issue of senior, secured, unlisted redeemable and non- convertible debentures on private placement basis and other matters in relation to such issue.

Wanbury F&O

Wanbury Shareholding Pattern

43.02%
0%
0.59%
0%
42.16%
14.23%

Wanbury FAQs

Wanbury share price is ₹269 As on 22 April, 2026 | 23:42

The Market Cap of Wanbury is ₹942.2 Cr As on 22 April, 2026 | 23:42

The P/E ratio of Wanbury is 14.6 As on 22 April, 2026 | 23:42

The PB ratio of Wanbury is 7.7 As on 22 April, 2026 | 23:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23